GLP-1 Semaglutide for Weight Loss: Separating Fact from Misconception

The myth that semaglutide is a 'fat-burning injection'

Walk into any online forum and you will find semaglutide described as a fat burner, a metabolism booster, or even a shortcut. None of those framings are accurate. Semaglutide is a synthetic version of a hormone your gut already makes (GLP-1, or glucagon-like peptide-1) which is released naturally after you eat. Its job is to signal fullness to the brain, slow the movement of food from the stomach into the small intestine, and modulate how your body handles blood sugar. The injectable version simply keeps those signals active for longer and at a higher intensity than your body would manage on its own.

The practical result is that food becomes less compelling. People on semaglutide consistently report that the pull towards snacking or large portions fades. That shift is hormonal, not motivational. It is also why the medicine works best alongside a reduced-calorie diet and regular activity, it lowers the appetite threshold; you still have to choose what you eat within that new threshold. The NHS medicines page on semaglutide explains this mechanism clearly and is worth reading before you start any treatment.

Understanding this distinction matters for realistic expectations. Semaglutide is not doing something to your fat cells directly. It is reshaping the hormonal conversation between your gut and your brain, and that, across thousands of trial participants, produces meaningful, sustained weight reduction over months.

Ozempic versus Wegovy: the same molecule, different licences

A question our prescribers field most weeks: 'Can I use Ozempic for weight loss?' The short answer is no, not legally on a private weight-loss prescription. Ozempic contains semaglutide, as does Wegovy, but the two products carry different UK licences from the MHRA. Ozempic is authorised for managing type 2 diabetes. Wegovy is authorised for weight management in adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure or high cholesterol.

This distinction is not a technicality. Prescribing a medicine outside its licensed indication carries clinical and legal implications; a responsible prescriber working within a regulated pharmacy will not do it. If you have been offered 'Ozempic for weight loss' without a clinical assessment confirming a diabetes context, that is a red flag worth taking seriously. You can learn more about the full weight-management licence on our Wegovy overview page.

There is also a newer development worth knowing about. Wegovy now has a 7.2 mg dose option (the MHRA approved a dedicated single-dose 7.2 mg pen in April 2026) which in trials produced around 20.7% average weight loss over 72 weeks. That figure is closer to tirzepatide territory than the original 2.4 mg maintenance dose. Whether any specific dose or pen format is available is something confirmed at consultation, not assumed.

Who semaglutide is and is not licensed for

The licensed eligibility criteria in the UK are set out in the Wegovy SmPC and endorsed by NICE's appraisal of semaglutide for weight management (NICE TA875). Privately, the core threshold is a BMI of 30 or above, or 27 or above with at least one qualifying weight-related condition. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure alone is never the whole story; the prescriber reviews your health history, current medicines, and any conditions that might affect suitability.

The medicine is not recommended during pregnancy, breastfeeding, or when actively trying to conceive. It is not licensed for anyone under 18. Certain conditions (including a personal or family history of medullary thyroid carcinoma, or a history of pancreatitis) require careful prescriber discussion before treatment is considered. These exclusions exist because semaglutide is a powerful hormonal intervention; the clinical assessment is the safeguard, not a bureaucratic hurdle.

On the NHS, access to Wegovy sits within specialist weight management services and comes with a two-year maximum treatment duration under NICE criteria. Waiting lists are commonly long. Private treatment through a GPhC-registered online pharmacy is the practical alternative for people who do not meet NHS criteria or cannot wait, subject to the same clinical assessment standards. If you want to understand how cost factors into that decision, our page on Wegovy pricing in the UK covers what a legitimate private prescription typically includes.

Side effects and what to watch for

Gastrointestinal effects are the most common: nausea, loose stools, constipation, indigestion, and burping tend to cluster around the start of treatment and after each dose increase. For most people they settle within a week or two. Keeping meals smaller and lower in fat during the adjustment period helps; a pharmacist or prescriber can advise on specifics.

Less common but more urgent: any severe, persistent stomach pain that radiates toward the back (with or without vomiting) should prompt same-day medical contact, as this can indicate pancreatitis, which the MHRA flagged in a January 2026 Drug Safety Update for GLP-1 medicines. Symptoms of an allergic reaction (swelling, breathing difficulty, hives) also need immediate attention. If you notice anything unexpected, the MHRA's Yellow Card scheme lets you report suspected side effects directly.

A note on routine: the weekly injection is given subcutaneously, abdomen, thigh, or upper arm, rotating sites each week. Most people settle into a habit around the same day and time. Keeping the pen in the fridge door means it is easy to spot on injection day without disrupting the storage temperature. Exact storage guidance, including any permitted time outside the fridge, is set out in the Patient Information Leaflet, that document takes precedence over any general advice.

For a broader look at how semaglutide treatment fits into an overall weight-management plan, the semaglutide overview on our site goes into further detail, and if you are also taking other medicines, our guidance on combining melatonin and Wegovy is worth reviewing before you start. If you have specific questions before deciding whether to start, our FAQs page addresses some of the most common ones, including detailed information on semaglutide at the 1 mg dose stage and what to expect when you move on to semaglutide at the 2 mg dose stage. When you are ready to discuss whether this is the right option for you, a free consultation with our prescribers is the natural next step, check your eligibility here.